Cargando…

Green HPLC method with time programming for the determination of the co-formulated eye drops of tafluprost and timolol in their challengeable ratio

A new, simple and selective HPLC method was implemented for the simultaneous estimation of tafluprost (TFL) and timolol (TIM) in their new anti-glaucoma combination in the challengeable ratio of 3 and 1000 for TFL and TIM, respectively. Separation was achieved using a BDS Hypersil phenyl column and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abd-AlGhafar, Walaa Nabil, Aly, Fatma Ahmed, Sheribah, Zeinab Awad, Saad, Samar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9019973/ https://www.ncbi.nlm.nih.gov/pubmed/35440055 http://dx.doi.org/10.1186/s13065-022-00815-z

Ejemplares similares

Factorial design-assisted reverse phase HPLC–UV approach for the concurrent estimation of cetirizine and azelastine in aqueous humor
por: Abd-AlGhafar, Walaa Nabil, et al.
Publicado: (2022)

Synchronous Fluorescence as a Green and Selective Method for the Simultaneous Determination of Cetirizine and Azelastine in Aqueous Humor
por: Abd-AlGhafar, Walaa Nabil, et al.
Publicado: (2022)

Changes in ocular signs and symptoms in patients switching from bimatoprost–timolol to tafluprost–timolol eye drops: an open-label phase IV study
por: Bourne, Rupert Richard Alexander, et al.
Publicado: (2019)

Switching from concomitant therapy to tafluprost/timolol fixed combination
por: Inoue, Kenji, et al.
Publicado: (2018)

Efficacy and safety of the fixed combinations of tafluprost/timolol and latanoprost/carteolol
por: Fuwa, Masahiro, et al.
Publicado: (2019)

Efficacy and Safety of Switching from Tafluprost to a Tafluprost/Timolol Fixed Combination in Patients With Primary Open-Angle Glaucoma
por: Inoue, Kenji, et al.
Publicado: (2018)

Advantages of Efficacy and Safety of Fixed-Dose Tafluprost/Timolol Combination Over Fixed-Dose Latanoprost/Timolol Combination
por: Fuwa, Masahiro, et al.
Publicado: (2016)

The 24-hour intraocular pressure control by tafluprost/timolol fixed combination after switching from the concomitant use of tafluprost and timolol gel-forming solution, in patients with primary open-angle glaucoma
por: Nakamoto, Kenji, et al.
Publicado: (2018)

Efficacy and Safety of Switching Prostaglandin Analog Monotherapy to Tafluprost/Timolol Fixed-Combination Therapy
por: Kitamura, Kazuyoshi, et al.
Publicado: (2018)

Assessment of the optic nerve head, peripapillary, and macular microcirculation in the newly diagnosed patients with primary open-angle glaucoma treated with topical tafluprost and tafluprost/timolol fixed combination
por: Kurysheva, Natalia Ivanovna
Publicado: (2019)

The signs of ocular-surface disorders after switching from latanoprost to tafluprost/timolol fixed combination: a prospective study
por: Okumichi, Hideaki, et al.
Publicado: (2017)

Fixed-Dose Combination of Tafluprost and Timolol in the Treatment of Open-Angle Glaucoma and Ocular Hypertension: Comparison with Other Fixed-Combination Products
por: Holló, Gábor, et al.
Publicado: (2014)

Comparison of Ocular Pulse Amplitude Lowering Effects of Preservative-Free Tafluprost and Preservative-Free Dorzolamide-Timolol Fixed Combination Eyedrops
por: Seo, Du Ri, et al.
Publicado: (2015)

Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study
por: Oddone, Francesco, et al.
Publicado: (2020)

Correction to: Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study
por: Oddone, Francesco, et al.
Publicado: (2020)

Safety and efficacy of switching from dorzolamide 1.0%/timolol maleate 0.5% eye drops to brinzolamide 1.0%/timolol maleate 0.5% eye drops
por: Inoue, Kenji, et al.
Publicado: (2015)

Treatment of open-angle glaucoma and ocular hypertension with preservative-free tafluprost/timolol fixed-dose combination therapy: 6 case reports and clinical outcomes
por: Ansari, E., et al.
Publicado: (2022)

Treatment of Open-Angle Glaucoma and Ocular Hypertension with the Fixed-Dose Combination of Preservative-Free Tafluprost/Timolol: Clinical Outcomes from Ophthalmology Clinics in Italy
por: Oddone, Francesco, et al.
Publicado: (2022)

Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: UK and Ireland Results from the VISIONARY Study
por: Ansari, Ejaz, et al.
Publicado: (2021)

Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: Results from the VISIONARY Study Population in Spain
por: Garcia-Medina, Jose J., et al.
Publicado: (2022)

Postprandial Head-drops: Insight into Systemic Effects of Ocular Timolol Preparation in Elderly
por: Bin Waqar, Syed Hamza, et al.
Publicado: (2019)

Risk factors for periorbital dermatitis in patients using dorzolamide/timolol eye drops
por: Kim, Myungjin, et al.
Publicado: (2021)

Effects of timolol maleate eye drops on experimentally dilated cardiomyopathy and healthy rabbits
por: Isaka, Mitsuhiro, et al.
Publicado: (2021)

Quality of dorzolamide hydrochloride and timolol maleate containing eye drops distributed online
por: Merczel, Sára, et al.
Publicado: (2023)

Prospective Observational Post-marketing Study of Tafluprost 0.0015%/Timolol 0.5% Combination Ophthalmic Solution for Glaucoma and Ocular Hypertension: Short-Term Efficacy and Safety
por: Takagi, Yasutaka, et al.
Publicado: (2016)

Preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% in patients with open-angle glaucoma and ocular hypertension: results of an open-label observational study
por: Pillunat, Lutz E, et al.
Publicado: (2017)

Efficacy of the travoprost/timolol fixed combination versus the concomitant use of travoprost 0.004% and timolol 0.1% gel formulation
por: Kozobolis, Vassilios, et al.
Publicado: (2018)

Effects of Tafluprost on Ocular Blood Flow
por: Zhang, Xinyue, et al.
Publicado: (2022)

Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients
por: Ruangvaravate, Ngamkae, et al.
Publicado: (2020)

Development and validation of a reversed-phase HPLC method for analysis of tetrahydrozoline hydrochloride in eye drop formulations
por: Al-Rimawi, Fuad, et al.
Publicado: (2012)

Effect of preserved and preservative-free timolol eye drops on tear film stability in healthy Africans
por: Ilechie, Alex, et al.
Publicado: (2016)

Complete atrioventricular block due to timolol eye drops: a case report and literature review
por: Wang, Zhuoying, et al.
Publicado: (2019)

Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment
por: Oddone, Francesco, et al.
Publicado: (2022)

Comparative study to assess efficacy and safety of brinzolamide1% and timolol0.5% fixed combination eye drops versus dorzolamide2% and timolol0.5% fixed combination eye drops in management of open-angle glaucoma
por: Agarwal, Prerana, et al.
Publicado: (2022)

Long term safety and tolerability of Tafluprost 0.0015% vs Timolol 0.1% preservative-free in ocular hypertensive and in primary open-angle glaucoma patients: a cross sectional study
por: Rolle, Teresa, et al.
Publicado: (2017)

Correction to: Switching to Preservative-Free Tafluprost/Timolol Fixed-Dose Combination in the Treatment of Open-Angle Glaucoma or Ocular Hypertension: Subanalysis of Data from the VISIONARY Study According to Baseline Monotherapy Treatment
por: Oddone, Francesco, et al.
Publicado: (2022)

Benefits of switching from latanoprost to preservative-free tafluprost eye drops: a meta-analysis of two Phase IIIb clinical trials
por: Uusitalo, Hannu, et al.
Publicado: (2016)

A 6-Month Study Comparing Efficacy, Safety, and Tolerability of the Preservative-free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% versus Each of Its Individual Preservative-Free Components
por: Pfeiffer, Norbert, et al.
Publicado: (2014)

Efficacy, Safety and Patient-Reported Outcomes with Preservative-Free (PF) Tafluprost or PF-Dorzolamide/Timolol Compared with Preserved Latanoprost: A Prospective Multicenter Study in Korean Glaucoma Patients with Ocular Surface Disease
por: Park, Sang-Woo, et al.
Publicado: (2022)

Preservative toxicity in glaucoma medication: clinical evaluation of benzalkonium chloride-free 0.5% timolol eye drops
por: Rosin, Lauren M, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_iav1373060j0saqedjt6nvmfrc